CYBN
Cybin Inc.
Set alert
- YTD
- +1.22%
- 1 year
- -12.01%
- Open
- 8.28
- Prev close
- 8.28
- Mkt cap
- 190.72M
- Vol
- 716.53K
- Avg vol
- 352.19K
- EPS
- -5.97
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 8.14
- High
- 8.38
- Forward P/E
- -1.98
- Beta
- 0.89
- Short ratio
- 4.07
- Inst. own
- 36.61%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Feb 12, 2025
- 50-d avg
- 10.44
- 200-d avg
- 11.48
- 1y target
- 101.46
Key statistics
- Market cap
- 190.72M
- Enterprise value
- 40.85M
- Trailing P/E
- 0.00
- Forward P/E
- -1.98
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 0.67
- EPS (TTM)
- -5.97
- Beta
- 0.89
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 0
- Revenue growth
- 0.00%
- Free cash flow
- -50.43M
- Total cash
- 183.28M
- Total debt
- 212.00K
- Return on equity
- -49.07%
- Shares outstanding
- 19.99M
- Short % of float
- 0.00%
- 50-day average
- 10.44
- 200-day average
- 11.48
Analyst view
Consensus: none
- Target (low)
- 24.44
- Target (mean)
- 101.46
- Target (high)
- 185.72
- Strong buy1
- Buy4
- Hold0
- Sell0
- Strong sell0
Next earnings
Feb 12, 2025
Expected Feb 12, 2025. Consensus EPS estimate -1.57.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Feb 12, 2025 | Dec 1, 2024 | -0.53 | — | — | — |
| Nov 13, 2024 | Sep 1, 2024 | -0.38 | -2.10 | -1.72 | -452.63% |
| Aug 8, 2024 | Jun 1, 2024 | 0.00 | — | — | — |
| Aug 8, 2024 | Jun 1, 2024 | 0.00 | -0.38 | — | — |
| Jun 26, 2024 | Mar 1, 2024 | -0.76 | — | — | — |
| Jun 26, 2024 | Mar 1, 2024 | -0.76 | -1.52 | -0.76 | -100.00% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 19, 2024 | Canaccord Genuity | main | Buy | Buy |
| Nov 19, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Nov 18, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Nov 14, 2024 | Canaccord Genuity | main | Buy | Buy |
| Sep 23, 2024 | Canaccord Genuity | main | Buy | Buy |
| Aug 23, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
About Cybin Inc.
Cybin Inc., a clinical-stage biopharmaceutical company, focuses on developing psychedelic-based therapeutics for patients with mental health conditions. The company's development pipeline includes CYB003, a deuterated psilocybin analog, which is in phase 1/2a clinical trial to treat major depressive disorder (MDD), as well as in preclinical trials for alcohol use disorder; CYB004, a deuterated dimethyltryptamine (DMT), which completed phase 2 clinical trial for treating generalized anxiety disorders; SPL028 injectable deuterated DMT completed phase 1 clinical intramuscular and intravenous trial; SPL026 completed phase 1, 1b, and 1/2a for MDD; and CYB005, a phenethylamine derivative, which in preclinical stage to treat neuroinflammation, as well as has a research pipeline of investigational psychedelic-based compounds. The company has research and collaboration agreement with TMS Neurohealth Centers Inc. for development of psychedelic compound-based therapeutics; Kernel for use of Kernel flow technology to measure neural activity; and Greenbook TMS to establish mental health centers. The company is headquartered in Toronto, Canada.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- Canada
- Website
- cybin.com
News
- Cybin Shareholders Weigh Helus Pharma Rebrand, Eight-Member Board
- Cybin Eyes Q4 Phase 3 Data for Depression Drug HLP003
- Cybin Eyes Q4 Phase III Depression Readout as Psychedelic Pipeline Advances
- Johnson & Johnson’s Spravato sales growth supports psychedelic drug opportunity: Jefferies
- CleanSpark shares surge after company secures $6.6B data center lease agreement
- Tower Semiconductor shares jump as company announces Japan expansion to boost silicon photonics capacity
- Cybin: A Speculative Bet On Their Pivotal Depression Readout
- BetterLife Pharma Announces Appointment of Doug Drysdale as Executive Chairman and Director
- Cybin: Regulatory Tailwinds Unlock Asymmetric Upside (Rating Upgrade)
- FTSE 100 Live: London stocks slide as aerospace and defence sector falls
Your note
Sign in to keep a note on CYBN — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| Cavers (Gregory Joseph) | Senior Officer of Issuer | Acquisition or disposition in the public market | Jun 28, 2022 | 40,000 |
| Drysdale (Douglas Lee) | Senior Officer of Issuer | Acquisition or disposition in the public market | Mar 23, 2022 | 38,000 |
| Fahel (Gabriel) | Senior Officer of Issuer | Acquisition or disposition in the public market | Mar 23, 2022 | 124,000 |
| Firestone (Theresa) | Director of Issuer | Acquisition or disposition in the public market | Jun 26, 2022 | 40,250 |
| Greene (Brett) | Senior Officer of Issuer | Acquisition or disposition pursuant to a take-over bid, merger or acquisition | Aug 30, 2022 | 433,075 |
| Hoskins (Eric William) | Director of Issuer | Acquisition or disposition in the public market | Jun 29, 2022 | 50,000 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Deep Track Capital, Lp | 7.65% | 1,529,987 | 14.60M | Sep 29, 2024 |
| Rosalind Advisors, Inc. | 5.38% | 1,075,105 | 10.26M | Sep 29, 2024 |
| Sphera Funds Management Ltd. | 4.67% | 933,225 | 8.90M | Sep 29, 2024 |
| Avidity Partners Management, LP | 4.59% | 918,000 | 8.76M | Sep 29, 2024 |
| Logos Global Management LP | 3.00% | 600,000 | 5.72M | Sep 29, 2024 |
| Octagon Capital Advisors LP | 2.45% | 489,596 | 4.67M | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| AdvisorShares Trust-AdvisorShares Psychedelics ETF | 0.24% | 47,541 | 453.54K | Oct 30, 2024 |